- Home
- ROIC vs KROS Comparison
ROIC vs KROS Comparison
Compare ROIC & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIC
- KROS
- Stock Information
- Founded
- ROIC 2007
- KROS 2015
- Country
- ROIC United States
- KROS United States
- Employees
- ROIC N/A
- KROS N/A
- Industry
- ROIC Real Estate Investment Trusts
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- ROIC Real Estate
- KROS Health Care
- Exchange
- ROIC Nasdaq
- KROS Nasdaq
- Market Cap
- ROIC 2.2B
- KROS 633.5M
- IPO Year
- ROIC N/A
- KROS 2020
- Fundamental
- Price
- ROIC $17.36
- KROS $15.92
- Analyst Decision
- ROIC Hold
- KROS Buy
- Analyst Count
- ROIC 6
- KROS 11
- Target Price
- ROIC $15.75
- KROS $68.83
- AVG Volume (30 Days)
- ROIC 1.1M
- KROS 1.9M
- Earning Date
- ROIC 02-12-2025
- KROS 02-26-2025
- Dividend Yield
- ROIC 3.46%
- KROS N/A
- EPS Growth
- ROIC 57.91
- KROS N/A
- EPS
- ROIC 0.46
- KROS N/A
- Revenue
- ROIC $336,785,000.00
- KROS $651,000.00
- Revenue This Year
- ROIC N/A
- KROS $224.66
- Revenue Next Year
- ROIC $0.97
- KROS N/A
- P/E Ratio
- ROIC $37.85
- KROS N/A
- Revenue Growth
- ROIC 4.18
- KROS 8037.50
- 52 Week Low
- ROIC $11.87
- KROS $15.33
- 52 Week High
- ROIC $17.52
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- ROIC 56.92
- KROS 22.66
- Support Level
- ROIC $17.34
- KROS $15.33
- Resistance Level
- ROIC $17.40
- KROS $17.25
- Average True Range (ATR)
- ROIC 0.04
- KROS 1.37
- MACD
- ROIC -0.04
- KROS -0.48
- Stochastic Oscillator
- ROIC 45.00
- KROS 10.31
About ROIC Retail Opportunity Investments Corp. (MD)
Retail Opportunity Investments Corp is a self-managed real estate investment trust. The company specializes in the acquisition, ownership and management of necessity-based community and neighborhood shopping centers on the west coast of the United States, anchored by supermarkets and drugstores. The Company's primary business is the ownership, management, and redevelopment of retail real estate properties.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.